文献速递肿瘤 PET/CT甲状腺核医学

功能成像与免疫组化标志物的关系及乳腺癌亚型预测:一项PET/MRI研究

Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-25

这项前瞻性研究纳入50例初诊乳腺癌患者,在药物和手术治疗前接受PET/MRI检查,提取形态学、弥散、灌注和代谢参数,并与免疫组化标志物进行相关性分析。ROC分析显示SUVmax、SUVmean、SUL可区分管腔A型与管腔B型及非管腔型,Kepmax可区分管腔A型与管腔B型,Ktransmax可区分管腔A型与非管腔型,ADC可区分管腔B型与非管腔型。多因素分析构建的包含Ktransmax和SUVmax的预后模型在49例患者中正确预测38例(77.6%,p < 0.001),对管腔B型亚型的准确率更高(86.2%)。

要点

  • SUVmax、SUVmean和SUL可区分管腔A型与管腔B型及非管腔型乳腺癌,最低SUV和SUL值见于管腔A型。
  • Kepmax可区分管腔A型与管腔B型(AUC=0.779),最高值见于管腔B型。
  • 包含Ktransmax和SUVmax的预测模型在49例中正确预测38例亚型(77.6%,p < 0.001),管腔B型准确率86.2%。

核心结论

  • 使用PET和MRI参数的多因素分析构建的包含Ktransmax和SUVmax的预后模型能够在49例患者中预测38例的肿瘤亚型(77.6%,p < 0.001),对管腔B型亚型的准确率更高(86.2%)。

研究设计与样本

  • 前瞻性研究,经机构伦理委员会批准,所有患者提供书面知情同意。
  • 共纳入50例初诊乳腺癌患者,在药物和手术治疗前接受PET/MRI检查。

主要发现

  • SUVmax、SUVmean和SUL可区分管腔A型与管腔B型(AUCSUVmean=0.799;AUCSUVmax=0.833;AUCSUL=0.813)及管腔A型与非管腔型(AUCSUVmean=0.926;AUCSUVmax=0.917;AUCSUL=0.945),最低SUV和SUL值与管腔A型相关。
  • Kepmax可区分管腔A型与管腔B型(AUC=0.779),最高值与管腔B型相关。
  • Ktransmax可区分管腔A型与非管腔型(AUC=0.881),最高灌注值与不非管腔型相关。
  • ADC可区分管腔B型与非管腔型(AUC=0.877),最低ADCmean值与管腔B型相关。
  • 多因素分析构建的预后模型包含Ktransmax和SUVmax参数,在49例患者中正确预测38例亚型(77.6%,p < 0.001),管腔B型准确率86.2%。

关键数值与推荐

  • SUVmax、SUVmean和SUL区分管腔A型与管腔B型的AUC分别为0.833、0.799和0.813。
  • SUVmax、SUVmean和SUL区分管腔A型与非管腔型的AUC分别为0.917、0.926和0.945。
  • Kepmax区分管腔A型与管腔B型的AUC为0.779。
  • Ktransmax区分管腔A型与非管腔型的AUC为0.881。
  • ADC区分管腔B型与非管腔型的AUC为0.877。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to determine if functional parameters extracted from the hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) correlate with the immunohistochemical markers of breast cancer (BC) lesions, to assess their ability to predict BC subtype. METHODS: This prospective study was approved by the institution's Ethics Committee, and all patients provided written informed consent. A total of 50 BC patients at diagnosis underwent PET/MRI before pharmacological and surgical treatment. For each primary lesion, the following data were extracted: morphological data including tumour-node-metastasis stage and lesion size; apparent diffusion coefficient (ADC); perfusion data including forward volume transfer constant (Ktrans), reverse efflux volume transfer constant (Kep) and extravascular extracellular space volume (Ve); and metabolic data including standardized uptake value (SUV), lean body mass (SUL), metabolic tumour volume and total lesion glycolysis. Immunohistochemical reports were used to determine receptor status (oestrogen, progesterone, and human epidermal growth factor receptor 2), cellular differentiation status (grade), and proliferation index (Ki67) of the tumour lesions. Correlation studies (Mann-Whitney U test and Spearman's test), receiver operating characteristic (ROC) curve analysis, and multivariate analysis were performed. RESULTS: Association studies were performed to assess the correlations between imaging and histological prognostic markers of BC. Imaging biomarkers, which significantly correlated with biological markers, were selected to perform ROC curve analysis to determine their ability to discriminate among BC subtypes. SUVmax, SUVmean and SUL were able to discriminate between luminal A and luminal B subtypes (AUCSUVmean = 0.799; AUCSUVmax = 0.833; AUCSUL = 0.813) and between luminal A and nonluminal subtypes (AUCSUVmean = 0.926; AUCSUVmax = 0.917; AUCSUL = 0.945), and the lowest SUV and SUL values were associated with the luminal A subtype. Kepmax was able to discriminate between luminal A and luminal B subtypes (AUC = 0.779), and its highest values were associated with the luminal B subtype. Ktransmax (AUC = 0.881) was able to discriminate between luminal A and nonluminal subtypes, and the highest perfusion values were associated with the nonluminal subtype. In addition, ADC (AUC = 0.877) was able to discriminate between luminal B and nonluminal subtypes, and the lowest ADCmean values were associated with the luminal B subtype. Multivariate analysis was performed to develop a prognostic model, and the best predictive model included Ktransmax and SUVmax parameters. CONCLUSION: Using multivariate analysis of both PET and MRI parameters, a prognostic model including Ktransmax and SUVmax was able to predict the tumour subtype in 38 of 49 patients (77.6%, p < 0.001), with higher accuracy for the luminal B subtype (86.2%).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Incoronato M, Grimaldi AM, Cavaliere C, et al. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study. Eur J Nucl Med Mol Imaging. 2018. PMID: 29696443. doi:10.1007/s00259-018-4010-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。